A calm evidence note
Noopept vs Piracetam: How the Two 'Racetam-Family' Nootropics Compare
Compare the noopept and piracetam head-to-head study, its limits for everyday focus, and FDA action on unapproved drug claims.
On this page
Our nootropic ranking
Five branded stacks, graded on trials
Ranked on whether the finished product — not just an ingredient in it — was ever put in a published trial, and how the actives are dosed against the studied range.
Compare nootropic stacksNot an ad · none of the five is an affiliate partner, no row links to a seller, and nothing in that ranking is ordered by money.
An older clinical study compared noopept with piracetam in patients with cognitive symptoms following vascular or traumatic brain disease.1 The study helps explain why the compounds are discussed together. It gives little guidance for a healthy adult seeking better everyday focus.
This is a comparison of two unapproved research chemicals, not a treatment recommendation, and nothing here is medical advice. Neither piracetam nor noopept is approved by the FDA to treat, prevent, or cure brain fog, memory problems, or any condition. If your focus or memory problems are new, worsening, or interfering with daily life, the responsible first move is to rule in a real, treatable cause — sleep debt, thyroid or iron issues, B12 deficiency, depression, medication side effects — before reaching for an obscure compound from either family.
The shared family tree
Piracetam is the original racetam — the prototype of the class, first synthesized in the 1960s, and the compound the entire category is named after. Noopept (omberacetam) is often called "racetam-adjacent" because it was developed in the same Russian research lineage and aimed at the same goals, but it is structurally a synthetic dipeptide rather than a true racetam. So they are cousins, not twins. They were designed in the same tradition, are proposed to work through overlapping cholinergic and glutamatergic pathways, and crucially, both built their reputations on the same kind of evidence: small, older, mostly Russian and European clinical trials in people with cognitive impairment — not large modern Western randomized trials in healthy adults.
Noopept vs piracetam at a glance
| Noopept (omberacetam) | Piracetam | |
|---|---|---|
| Compound class | Synthetic dipeptide, "racetam-adjacent" | The original racetam — prototype of the class |
| Amounts used in the comparison | Lower amount by weight | Higher amount by weight |
| Strongest human evidence | Small, older trials in cognitive impairment; the head-to-head vs piracetam | Older, mixed trials in cognitive decline and recovery populations |
| Large healthy-adult RCTs | Essentially none in Western literature | Essentially none in Western literature |
| US regulatory status | No FDA-approved indication | No FDA-approved indication |
| Online product quality | Trial cannot establish seller quality | Trial cannot establish seller quality |
What the different trial amounts tell us
The head-to-head trial gave substantially less noopept by weight than piracetam.1 The amount of each compound chosen for a trial does not establish a pharmacological potency ratio.
To compare potency, researchers would need evidence about the response to different amounts of each compound under comparable conditions. This study provides no basis for the claim that noopept is a thousand times more potent.
The head-to-head trial — and what it really says
The reason these two are paired so often is the comparative study by Neznamov and Teleshova, which tested noopept directly against piracetam in patients with mild cognitive disorders arising from organic brain disease of vascular and traumatic origin1. The trial reported that noopept produced benefit on cognitive and related symptoms — comparable to, and in some respects favorable versus, piracetam — and that both were generally well tolerated1.
It's tempting to read that as "noopept beats piracetam," but the honest reading is more restrained. First, this was a study in patients with diagnosed mild cognitive impairment from vascular and traumatic brain injury — not healthy adults chasing sharper everyday focus. Second, it is a small, older trial from the Russian clinical-research tradition, which is where most of the literature for both compounds lives. Third, "comparable to piracetam" is the operative phrase: the most-cited result places noopept in the same ballpark as piracetam, which itself is an old compound with modest, contested evidence. So the head-to-head doesn't crown a winner for healthy people — it mostly confirms that the two belong to the same evidence tier1. Our review of the noopept studies examines the population and outcomes behind that comparison.
The honest verdict
What actually separates these two
- Evidence quality is roughly tied — both rest on small, older, mostly non-Western trials in impaired patients, with no large healthy-adult RCTs behind either.
- The study used different amounts by weight. It did not measure a potency ratio.
- The FDA has taken action against products marketed with unapproved drug claims.
- For everyday focus in a healthy person, efficacy is not well established for either — better-evidenced, better-regulated options make more sense.
What's missing for both
The most important fact about this comparison is what neither compound has. What would actually settle the focus question is large, modern, independent, placebo-controlled randomized trials in healthy people measuring attention, processing speed, or memory. Those essentially do not exist in the mainstream Western literature for piracetam or noopept. Piracetam has more total studies by sheer age and volume, but they skew toward older trials in cognitive decline, dementia, and recovery populations, with mixed and often unimpressive results — not clean demonstrations of benefit in rested, healthy adults. Noopept's human record is even thinner and narrower. For everyday cognitive enhancement in a healthy person, efficacy is not well established for either one.
What the FDA has said about these products
Neither compound is an FDA-approved treatment. The FDA cited a seller for marketing noopept and piracetam with disease claims and identified those products as unapproved new drugs.2 The action concerns those marketed products and claims.
A research-use label does not establish that a product is suitable for human use, and the clinical paper does not establish the identity or purity of a product sold online.
So which one, if either?
The small clinical comparison does not establish which compound, if either, improves attention in healthy adults. It also provides little basis for judging longer-term safety.
How to think about it versus better options
If the real goal is focus or clearer thinking, both racetam-family compounds are hard to recommend over options that are better-evidenced and cleaner in regulatory status. We cover noopept's evidence in depth in our honest noopept review, and the choline nootropic citicoline (CDP-choline) has more direct human cognitive-outcome data and a long, generally clean tolerability record. For where everything sits when ranked by actual evidence quality, see our evidence-tiered guide to focus and concentration supplements and the best nootropics for focus guide. Our tools can also help you think through dosing and timing for the supplements that are genuinely worth using.
The bottom line
The head-to-head study reported selected outcomes in patients with cognitive impairment.1 The results cannot establish a focus benefit in healthy adults or a comparative potency ratio. If your concentration has changed, start with possible causes of brain fog.
A few gentle questions
Is noopept better than piracetam?
An older study in patients with cognitive disorders reported selected benefits. Its results do not establish a comparative advantage for healthy adults seeking better focus.
Why is noopept dosed in milligrams when piracetam needs grams?
The head-to-head study used less noopept than piracetam by weight. This difference in the amounts tested does not establish a potency ratio or an advantage for focus.
Are noopept and piracetam legal in the US?
Neither is an FDA-approved drug. The FDA has cited a seller for marketing noopept and piracetam products as unapproved drugs with disease claims. That action addressed particular marketed products and claims.
Which one should I take for focus?
The clinical evidence does not establish that either improves everyday focus in healthy adults. If concentration problems persist, talk with a clinician about possible causes.
Where this comes from
- Neznamov GG, Teleshova ES (2009). Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin. Neuroscience and Behavioral Physiology. https://pubmed.ncbi.nlm.nih.gov/19234797/
- U.S. Food and Drug Administration (2019). Peak Nootropics LLC aka Advanced Nootropics warning letter, MARCS-CMS 557887.. FDA. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Read on, gently
Noopept: What the Evidence Shows for Focus and Memory
Noopept is a popular synthetic nootropic, but its evidence rests on small, older Russian trials — with no large Western RCTs in healthy people. Honest review.
ReadNAD+ Nasal Spray: Does It Work for Focus?
NAD+ nasal spray is sold for focus and energy. No human trial has tested the route, it isn't FDA-approved, and here's how to compare prices and billing terms.
ReadEnhance MD NAD+ Review: Read the Four-Week Billing First
Enhance MD offers NAD+ injections and wafers. We compare four-week billing, longer plans, support, pharmacy disclosures and the limits of the evidence.
ReadNAD+ Injection Side Effects: Safety Questions Before Treatment
FDA reports, sterile-compounding risks, and limits of NAD+ injection evidence. What to ask a prescriber and how to respond to concerning symptoms.
ReadNAD+ vs Nootropics for Focus: An Honest Comparison
Neither NAD+ nor most nootropics have strong human focus evidence. An honest, evidence-tiered comparison — and the few things that modestly work.
ReadCiticoline (CDP-Choline) for Focus and Brain Fog: The Evidence
Citicoline is the best-evidenced choline nootropic, with small RCTs on attention and processing speed. Honest dosing, the alpha-GPC comparison, and the limits.
Read